Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

112.58USD
1:11pm EST
Change (% chg)

$-1.02 (-0.90%)
Prev Close
$113.60
Open
$113.94
Day's High
$114.93
Day's Low
$112.26
Volume
832,392
Avg. Vol
1,907,228
52-wk High
$149.34
52-wk Low
$96.18

Latest Key Developments (Source: Significant Developments)

Alexion Pharmaceuticals posts Q4 adj. earnings $1.26/shr
Thursday, 16 Feb 2017 06:30am EST 

Alexion Pharmaceuticals Inc : Alexion reports fourth quarter and full year 2016 results and provides financial guidance for 2017 . Q4 non-GAAP earnings per share $1.26 . Q4 GAAP earnings per share $0.41 . Q4 revenue $831 million versus I/B/E/S view $836.6 million . Q4 earnings per share view $1.25 -- Thomson Reuters I/B/E/S . Alexion Pharmaceuticals Inc - board of directors has increased size of company's share repurchase authorization to a total of $1 billion . Sees 2017 total revenues $3,400 million to $3,500 million . Alexion Pharmaceuticals Inc - GAAP guidance for 2017 earnings per share $2.55 to $3.05 . Sees 2017 earnings per share non-GAAP $5.00 to $5.25 . FY2017 earnings per share view $5.54, revenue view $3.54 billion -- Thomson Reuters I/B/E/S .Alexion Pharmaceuticals Inc - board's repurchase authorization is open-ended.  Full Article

Alexion interim CEO says company is not up for sale - conf
Monday, 9 Jan 2017 11:59am EST 

Alexion Pharmaceuticals Inc : Alexion interim CEO says they are not up for sale - JPM Healthcare conf . Alexion execs says growth is primarily coming from volume, not pricing- JPM Healthcare conf . Alexion execs say they are going to be very careful with cash deployment for m&a - JPM Healthcare conf . Alexion says they are not aware of any more investigations into Soliris sales practices, other than what they have already revealed - JPM Healthcare conf Further company coverage: [ALXN.O] ((Bangalore.newsroom@thomsonreuters.com ;)).  Full Article

Alexion submits U.S. and EU applications seeking approval of Soliris as a treatment for patients with refractory generalized myasthenia gravis
Monday, 9 Jan 2017 06:30am EST 

Alexion Pharmaceuticals Inc : Alexion submits U.S. and EU applications seeking approval of Soliris® (eculizumab) as a treatment for patients with refractory generalized myasthenia gravis (gMG) .Alexion Pharmaceuticals Inc - Both U.S. and EU submissions are supported by comprehensive data from phase 3 regain study.  Full Article

Paulson & Co cuts share stake in Alexion Pharmaceuticals, Johnson & Johnson
Monday, 14 Nov 2016 05:38pm EST 

Paulson & Co : Paulson & Co cuts share stake in Alexion Pharmaceuticals Inc by 15.0 percent to 227,700 shares . Paulson & Co ups share stake in Fedex Corp by 47 percent to 106,800 shares . Paulson & Co takes 74,000 share stake in Alder Biopharmaceuticals Inc . Paulson & Co takes share stake of 628,100 shares in eBay Inc . Paulson & Co cuts share stake in Johnson & Johnson by 72.7 percent to 35,000 shares .Paulson & Co - change in holdings are as of September 30, 2016 and compared with the previous quarter ended as of June 30, 2016.  Full Article

Alexion gets orphan drug designation for ALXN1007
Monday, 29 Aug 2016 04:33pm EDT 

Alexion Pharmaceuticals Inc : European Commission grants orphan drug designation to ALXN1007 for the treatment of patients with graft-versus-host disease (GVHD) .ALXN1007 is currently being evaluated in a phase 2 study in patients with newly diagnosed acute GI-GVHD.  Full Article

Alexion Pharmaceuticals-FDA recently completed routine current good manufacturing practice inspection of Co's Smithfield, Rhode Island Manufacturing Facility
Monday, 8 Aug 2016 04:41pm EDT 

Alexion Pharmaceuticals Inc : Fda recently completed routine current good manufacturing practice inspection of Co's Smithfield, Rhode island manufacturing facility . FDA observations also pertain to monitoring of water systems . Based on current information, alexion anticipates that supply of soliris to patients will not be interrupted . FDA observations pertain to completion, closure of certain investigations, validation of surface sampling methods .Based on current information, does not anticipate material financial impact to resolve outstanding fda concerns.  Full Article

Alexion reports Q2 non-gaap EPS $1.13
Thursday, 28 Jul 2016 06:30am EDT 

Alexion Pharmaceuticals Inc : Sees FY non gaap earnings per share $4.50 to $4.65 . Sees FY non gaap total revenues $3,050 to $3,100 million . FY2016 earnings per share view $5.05, revenue view $3.06 billion -- Thomson Reuters I/B/E/S . Alexion reports second quarter 2016 results . Q2 non-gaap earnings per share $1.13 . Q2 gaap earnings per share $0.51 . Q2 revenue $753 million versus I/B/E/S view $742.7 million . Q2 earnings per share view $1.17 -- Thomson Reuters I/B/E/S . Sees FY gaap earnings per share $1.91 to $2.26 .Sees FY gaap total revenues $3,050 to $3,100 million.  Full Article

Alexion Pharmaceuticals announces data from phase 1/2 study of ALXN1210
Friday, 10 Jun 2016 02:30am EDT 

Alexion Pharmaceuticals Inc : Late-Breaking data presented at EHA: all patients with pnh treated with once-monthly dosing of ALXN1210 in phase 1/2 study exhibit rapid and sustained reductions in ldhSays announced today that interim data were presented from a phase 1/2 study of ALXN1210 . Once-Monthly dosing of ALXN1210 achieved rapid and sustained reductions in mean levels of lactate dehydrogenase . Says no serious adverse events or study withdrawals were observed in either patient cohort . 2 patients experienced serious treatment-related adverse events and one patient had a grade 2 infusion-related reaction . Says six deaths were reported, none of which were considered related to treatment with ALXN1007 . Says were no grade 3 or higher non-serious adverse events related to treatment with ALXN1007 .Says one patient withdrew from study due to a treatment-emergent adverse event.  Full Article

Alexion announces topline results from Phase 3 regain study of eculizumab
Monday, 6 Jun 2016 04:01pm EDT 

Alexion Pharmaceuticals Inc : Alexion announces topline results from Phase 3 regain study of eculizumab (soliris) in patients with refractory generalized myasthenia gravis (GMG) . Primary endpoint of regain study missed statistical significance . Alexion continues to analyze data from regain study .Four patients receiving eculizumab (6.5 pct) discontinued treatment due to an adverse event.  Full Article

Alexion Pharmaceuticals says EC grants orphan drug designation to ALXN1210
Wednesday, 1 Jun 2016 04:05pm EDT 

Alexion Pharmaceuticals Inc :European Commission has granted orphan drug designation to ALXN1210.  Full Article

Elliott Management seeks changes at Alexion: NYT

U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.